Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
PURPOSE: To investigate the clinical manifestations and visual outcomes of leukemic retinopathy and optic neuropathy (LRON) in patients with acute leukemia. METHODS: We recruited 276 patients with acute leukemia, 55 of whom had LRON. The ophthalmic measurements, treatment courses, laboratory data, and molecular profiling were retrospectively collected. RESULTS: Patients with LRON were classified as type 1, type 2a, type 2b, and type 3. All patients with type 3 LRON had acute lymphoblastic leukemia (ALL), while the other types of LRON mainly occurred in patients with acute myeloid leukemia (AML). Patients with type 2b and type 3 LRON had worse initial best-corrected visual acuity (BCVA); none of the patients with type 3 LRON had recovery of BCVA during follow-up. The patients with AML with LRON were more likely to undergo hematopoietic stem cell transplantation (P < 0.001); their leukemic blasts more frequently expressed CD7 (P = 0.004) and CD38 (P = 0.048) and harbored DNMT3A (P = 0.017) and IDH1 (P = 0.041) mutations. Notably, the co-occurrence of DNMT3A, IDH1, and TET2 mutations was associated with a particularly high risk of LRON (odds ratio = 16.41). The patients with ALL with type 3 LRON had higher rates of central nervous system involvement (P = 0.041) and relapsed leukemia (P = 0.007). Nevertheless, the presence of LRON did not significantly affect survival in acute leukemia. CONCLUSIONS: We characterized distinct clinical, genetic features and visual outcomes across LRON subtypes. Our study highlights the importance of prompt ophthalmic consultation and patient education regarding visual symptoms in acute leukemia.